Discriminations of active from inactive HDAC8 inhibitors Part II: Bayesian classification study to find molecular fingerprints

References

• S.A. Amin, N. Adhikari, and T. Jha, Diverse classes of HDAC8 inhibitors: In search of molecular fingerprints that regulate activity, Future Med. Chem. 10 (2018), pp. 1589–1602. doi: 10.4155/fmc-2018-0005.
   PubMed Web of Science ®Google Scholar
• S.A. Amin, N. Adhikari, and T. Jha, Is dual inhibition of metalloenzymes HDAC-8 and MMP-2 a potential pharmacological target to combat hematological malignancies? Pharmacol. Res. 122 (2017), pp. 8–19. doi: 10.1016/j.phrs.2017.05.002.
   PubMed Web of Science ®Google Scholar
• M.M. Müller and T.W. Muir, Histones: At the crossroads of peptide and protein chemistry, Chem. Rev. 115 (2015), pp. 2296–2349. doi: 10.1021/cr5003529
   PubMed Web of Science ®Google Scholar
• A. Chakrabarti, I. Oehme, O. Witt, G. Oliveira, W. Sippl, C. Romier, R.J. Pierce, and M. Jung, HDAC8: A multifaceted target for therapeutic interventions, Trends Pharmacol. Sci. 36 (2015), pp. 481–492. doi: 10.1016/j.tips.2015.04.013
   PubMed Web of Science ®Google Scholar
• J. Roche and P. Bertrand, Inside HDACs with more selective HDAC inhibitors, Eur. J. Med. Chem. 121 (2016), pp. 451–483. doi: 10.1016/j.ejmech.2016.05.047.
   PubMed Web of Science ®Google Scholar
• S.A. Amin, N. Adhikari, and T. Jha, Structure–activity relationships of hydroxamate-based histone deacetylase-8 inhibitors: Reality behind anticancer drug discovery, Future Med. Chem. 9 (2017), pp. 2211–2237. doi: 10.4155/fmc-2017-0130
   PubMed Web of Science ®Google Scholar
• P. Bertrand, Inside HDAC with HDAC inhibitors, Eur. J. Med. Chem. 45 (2010), pp. 2095–2116. doi: 10.1016/j.ejmech.2010.02.030.
   PubMed Web of Science ®Google Scholar
• S. Banerjee, N. Adhikari, S.A. Amin, and T. Jha, Histone deacetylase 8 (HDAC8) and its inhibitors with selectivity to other isoforms: An overview, Eur. J. Med. Chem. 164 (2019), pp. 214–240. doi: 10.1016/j.ejmech.2018.12.039.
   PubMed Web of Science ®Google Scholar
• A. Chakrabarti, J. Melesina, F.R. Kolbinger, I. Oehme, J. Senger, O. Witt, W. Sippl, and M. Jung, Targeting histone deacetylase 8 as a therapeutic approach to cancer and neurodegenerative diseases, Future Med. Chem. 8 (2016), pp. 1609–1634. doi: 10.4155/fmc-2016-0117.
   PubMed Web of Science ®Google Scholar
• I.V. Gregoretti, Y.M. Lee, and H.V. Goodson, Molecular evolution of the histone deacetylase family: Functional implications of phylogenetic analysis, J. Mol. Biol. 338 (2004), pp. 17–31. doi: 10.1016/j.jmb.2004.02.006.
   PubMed Web of Science ®Google Scholar
• B. Wolff, N. Jänsch, W.O. Sugiarto, S. Frühschulz, M. Lang, R. Altintas, I. Oehme, and F.-J. Meyer-Almes, Synthesis and structure activity relationship of 1, 3-benzo-thiazine-2-thiones as selective HDAC8 inhibitors, Eur. J. Med. Chem. 184 (2019), pp. 111756. doi: 10.1016/j.ejmech.2019.111756
   PubMed Web of Science ®Google Scholar
• J.R. Somoza, R.J. Skene, B.A. Katz, C. Mol, J.D. Ho, A.J. Jennings, C. Luong, A. Arvai, J.J. Buggy, E. Chi, J. Tang, B.C. Sang, E. Verner, R. Wynands, E.M. Leahy, D.R. Dougan, G. Snell, M. Navre, M.W. Knuth, R.V. Swanson, D.E. McRee, and L.W. Tari, Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases, Structure 12 (2004), pp. 1325–1334. doi: 10.1016/j.str.2004.04.012.
   PubMed Web of Science ®Google Scholar
• M. Marek, T.B. Shaik, T. Heimburg, A. Chakrabarti, J. Lancelot, E. Ramos-Morales, C. Da Veiga, D. Kalinin, J. Melesina, D. Robaa, K. Schmidtkunz, T. Suzuki, R. Holl, E. Ennifar, R.J. Pierce, M. Jung, W. Sippl, and C. Romier, Characterization of histone deacetylase 8 (HDAC8) selective inhibition reveals specific active site structural and functional determinants, J. Med. Chem. 61 (2018), pp. 10000–10016. doi: 10.1021/acs.jmedchem.8b01087
   PubMed Web of Science ®Google Scholar
• N. Adhikari, S.A. Amin, and T. Jha, Selective and nonselective HDAC8 inhibitors: A therapeutic patent review, Pharm. Pat. Anal. 7 (2018), pp. 259–276. doi: 10.4155/ppa-2018-0019
   PubMed Web of Science ®Google Scholar
• B.S. Mann, J.R. Johnson, M.H. Cohen, R. Justice, and R. Pazdur, FDA approval summary: Vorinostat for treatment of advanced primary cutaneous T-cell lymphoma, Oncologist 12 (2007), pp. 1247–1252. doi: 10.1634/theoncologist.12-10-1247.
   PubMed Web of Science ®Google Scholar
• A. Quintás-Cardama, H. Kantarjian, Z. Estrov, G. Borthakur, J. Cortes, and S. Verstovsek, Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosis, Leuk. Res. 36 (2012), pp. 1124–1127. doi: 10.1016/j.leukres.2012.03.003
   PubMed Web of Science ®Google Scholar
• H.Z. Lee, V.E. Kwitkowski, P.L. Del Valle, M.S. Ricci, H. Saber, B.A. Habtemariam, J. Bullock, E. Bloomquist, Y. Li Shen, X.H. Chen, J. Brown, N. Mehrotra, S. Dorff, R. Charlab, R.C. Kane, E. Kaminskas, R. Justice, A.T. Farrell, and R. Pazdur, FDA approval: Belinostat for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma, Clin. Cancer Res. 21 (2015), pp. 2666–2670. doi: 10.1158/1078-0432.CCR-14-3119
   PubMed Web of Science ®Google Scholar
• M.P. Fenichel, FDA approves new agent for multiple myeloma, J. Natl. Cancer Inst. 107 (2015), pp. 6–7. doi: 10.1093/jnci/djv165.
   Google Scholar
• X. Lu, Z. Ning, Z. Li, H. Cao, and X. Wang, Development of chidamide for peripheral T-cell lymphoma, the first orphan drug approved in China, Intract. Rare Dis. Res. 5 (2016), pp. 185–191. doi: 10.5582/irdr.2016.01024
   PubMed Web of Science ®Google Scholar
• R.D. Cramer, The inevitable QSAR renaissance, J. Comput. Aided Mol. Des. 26 (2012), pp. 35–38. doi: 10.1007/s10822-011-9495-0.
   PubMed Web of Science ®Google Scholar
• G. Lambrinidis and A. Tsantili-Kakoulidou, Challenges with multi-objective QSAR in drug discovery, Expert Opin. Drug Discov. 13 (2018), pp. 851–859. doi: 10.1080/17460441.2018.1496079.
   PubMed Web of Science ®Google Scholar
• P. Polishchuk, Interpretation of quantitative structure-activity relationship models: Past, present, and future, J. Chem. Inf. Model. 57 (2017), pp. 2618–2639. doi: 10.1021/acs.jcim.7b00274.
   PubMed Web of Science ®Google Scholar
• Y.C. Lo, S.E. Rensi, W. Torng, and R.B. Altman, Machine learning in chemoinformatics and drug discovery, Drug Discov. Today 23 (2018), pp. 1538–1546. doi: 10.1016/j.drudis.2018.05.010.
   PubMed Web of Science ®Google Scholar
• J.O. Berger, Statistical Decision Theory and Bayesian Analysis, Springer Science & Business Media, New York, 2013.
   Google Scholar
• G.E.P. Box and G.C. Tiao, Bayesian Inference in Statistical Analysis, John Wiley & Sons, New York, 2011.
   Google Scholar
• S. Banerjee, N. Adhikari, S.A. Amin, and T. Jha, Structural exploration of tetrahydroisoquinoline derivatives as HDAC8 inhibitors through multi-QSAR modeling study, J. Biomol. Struct. Dyn. (2019), pp. 1–14. doi: 10.1080/07391102.2019.1617782
   Web of Science ®Google Scholar
• S.A. Amin, N. Adhikari, and T. Jha, Development of decision trees to discriminate HDAC8 inhibitors and non-inhibitors using recursive partitioning, J. Biomol. Struct. Dyn. (2019), pp. 1–8. doi: 10.1080/07391102.2019.1661876
   Web of Science ®Google Scholar
• Binding Data Base (Binding DB) a tool, available at http://www.bindingdb.org/ (accessed Oct 10, 2017).
   Google Scholar
• Discovery Studio 3.0 (DS 3.0), Accelrys Inc., CA, USA, 2015; available at http://www.accelrys.com.
   Google Scholar
• M. Cruz-Monteagudo, J.L. Medina-Franco, Y. Pérez-Castillo, O. Nicolotti, M.N. Cordeiro, and F. Borges, Activity cliffs in drug discovery: Dr Jekyll or Mr Hyde? Drug Discov. Today 19 (2014), pp. 1069–1080. doi: 10.1016/j.drudis.2014.02.003.
   PubMed Web of Science ®Google Scholar
• C.A. Lipinski, F. Lombardo, B.W. Dominy, and P.J. Feeney, Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings, Adv. Drug. Deliv. Rev. 46 (2001), pp. 3–26. doi: 10.1016/S0169-409X(00)00129-0.
   PubMed Web of Science ®Google Scholar
• D.F. Veber, S.R. Johnson, H.Y. Cheng, B.R. Smith, K.W. Ward, and K.D. Kopple, Molecular properties that influence the oral bioavailability of drug candidates, J. Med. Chem. 45 (2002), pp. 2615–2623. doi: 10.1021/jm020017n.
   PubMed Web of Science ®Google Scholar
• B. Bhardwaj, A.T.K. Baidya, S.A. Amin, N. Adhikari, T. Jha, and S. Gayen, Insight into structural features of phenyltetrazole derivatives as ABCG2 inhibitors for the treatment of multidrug resistance in cancer, SAR QSAR Environ. Res. 30 (2019), pp. 457–475. doi: 10.1080/1062936X.2019.1615545.
   PubMed Web of Science ®Google Scholar
• S.A. Amin, N. Adhikari, S. Bhargava, T. Jha, and S. Gayen, Structural exploration of hydroxyethylamines as HIV-1 protease inhibitors: New features identified, SAR QSAR Environ. Res. 29 (2018), pp. 385–408. doi: 10.1080/1062936X.2018.1447511.
   PubMed Web of Science ®Google Scholar
• T. Jha, N. Adhikari, A. Saha, and S.A. Amin, Multiple molecular modelling studies on some derivatives and analogues of glutamic acid as matrix metalloproteinase-2 inhibitors, SAR QSAR Environ. Res. 29 (2018), pp. 43–68. doi: 10.1080/1062936X.2017.1406986.
   PubMed Web of Science ®Google Scholar
• X.Y. Xia, E.G. Maliski, P. Gallant, and D. Rogers, Classification of kinase inhibitors using a bayesian model, J. Med. Chem. 47 (2004), pp. 4463–4470. doi: 10.1021/jm0303195.
   PubMed Web of Science ®Google Scholar
• D. Rogers, R.D. Brown, and M. Hahn, Using extended-connectivity fingerprints with Laplacian-modified Bayesian analysis in high-throughput screening follow-up, J. Biomol. Screen. 10 (2005), pp. 682–686. doi: 10.1177/1087057105281365.
   PubMed Web of Science ®Google Scholar
• A.E. Klon, J.F. Lowrie, and D.J. Diller, Improved naive Bayesian modeling of numeriacl data for absorption, distribution, metabolism and excretion (ADME) property prediction, J. Chem. Inf. Model. 46 (2006), pp. 1945–1956. doi: 10.1021/ci0601315.
   PubMed Web of Science ®Google Scholar
• P. Prathipati, N.L. Ma, and T.H. Keller, Global bayesian models for the prioritization of antitubercular agents, J. Chem. Inf. Model. 48 (2008), pp. 2362–2370. doi: 10.1021/ci800143n.
   PubMed Web of Science ®Google Scholar
• D. Rogers and M. Hahn, Extended-connectivity fingerprints, J. Chem. Inf. Model. 50 (2010), pp. 742–754. doi: 10.1021/ci100050t.
   PubMed Web of Science ®Google Scholar
• T. Fawcett, An introduction to ROC analysis, Pattern Recognit. Lett. 27 (2006), pp. 861–874. doi: 10.1016/j.patrec.2005.10.010.
   Web of Science ®Google Scholar
• J.C. Bressi, R. de Jong, Y. Wu, A.J. Jennings, J.W. Brown, S. O’Connell, L.W. Tari, R.J. Skene, P. Vu, M. Navre, X. Cao, and A.R. Gangloff, Benzimidazole and imidazole inhibitors of histone deacetylases: Synthesis and biological activity, Bioorg. Med. Chem. Lett. 20 (2010), pp. 3138–3141. doi: 10.1016/j.bmcl.2010.03.092.
   PubMed Web of Science ®Google Scholar
• S. Mahboobi, A. Sellmer, H. Höcher, C. Garhammer, H. Pongratz, T. Maier, T. Ciossek, and T. Beckers, 2-aroylindoles and 2-aroylbenzofurans with N-hydroxyacrylamide substructures as a novel series of rationally designed histone deacetylase inhibitors, J. Med. Chem. 50 (2007), pp. 4405–4418. doi: 10.1021/jm0703136.
   PubMed Web of Science ®Google Scholar
• S. Balasubramanian, J. Ramos, W. Luo, M. Sirisawad, E. Verner, and J.J. Buggy, A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas, Leukemia 22 (2008), pp. 1026–1034. doi: 10.1038/leu.2008.9.
   PubMed Web of Science ®Google Scholar
• J. Cai, H. Wei, K.H. Hong, X. Wu, X. Zong, M. Cao, P. Wang, L. Li, C. Sun, B. Chen, G. Zhou, J. Chen, and M. Ji, Discovery, bioactivity and docking simulation of Vorinostat analogues containing 1,2,4-oxadiazole moiety as potent histone deacetylase inhibitors and antitumor agents, Bioorg. Med. Chem. 23 (2015), pp. 3457–3471. doi: 10.1016/j.bmc.2015.04.028.
   PubMed Web of Science ®Google Scholar
• D.R. Reddy, F. Ballante, N.J. Zhou, and G.R. Marshall, Design and synthesis of benzodiazepine analogs as isoform-selective human lysine deacetylase inhibitors, Eur. J. Med. Chem. 127 (2017), pp. 531–553. doi: 10.1016/j.ejmech.2016.12.032.
   PubMed Web of Science ®Google Scholar
• C.M. Marson, C.J. Matthews, S.J. Atkinson, N. Lamadema, and N.S. Thomas, Potent and selective inhibitors of histone deacetylase-3 containing chiral oxazoline capping groups and a N-(2-aminophenyl)-benzamide binding unit, J. Med. Chem. 58 (2015), pp. 6803–6818. doi: 10.1021/acs.jmedchem.5b00545.
   PubMed Web of Science ®Google Scholar
• C.L. Hamblett, J.L. Methot, D.M. Mampreian, D.L. Sloman, M.G. Stanton, A.M. Kral, J.C. Fleming, J.C. Cruz, M. Chenard, N. Ozerova, A.M. Hitz, H. Wang, S.V. Deshmukh, N. Nazef, A. Harsch, B. Hughes, W.K. Dahlberg, A.A. Szewczak, R.E. Middleton, R.T. Mosley, J.P. Secrist, and T.A. Miller, The discovery of 6-amino nicotinamides as potent and selective histone deacetylase inhibitors, Bioorg. Med. Chem. Lett. 17 (2007), pp. 5300–5309. doi: 10.1016/j.bmcl.2007.08.023.
   PubMed Web of Science ®Google Scholar
• G.P. Cao, M. Arooj, S. Thangapandian, C. Park, V. Arulalapperumal, Y. Kim, Y.J. Kwon, H.H. Kim, J.K. Suh, and K.W. Lee, A lazy learning-based QSAR classification study for screening potential histone deacetylase 8 (HDAC8) inhibitors, SAR QSAR Environ. Res. 26 (2015), pp. 397–420. doi: 10.1080/1062936X.2015.1040453.
   PubMed Web of Science ®Google Scholar
• G.P. Cao, S. Thangapandian, M. Son, R. Kumar, Y.J. Choi, Y. Kim, Y.J. Kwon, H.H. Kim, J.K. Suh, and K.W. Lee, QSAR modeling to design selective histone deacetylase 8 (HDAC8) inhibitors, Arch. Pharm. Res. 39 (2016), pp. 1356–1369. doi: 10.1007/s12272-015-0705-5.
   PubMed Web of Science ®Google Scholar
• S. Debnath, T. Debnath, S. Bhaumik, S. Majumdar, A.M. Kalle, and V. Aparna, Discovery of novel potential selective HDAC8 inhibitors by combine ligand-based, structurebased virtual screening and in-vitro biological evaluation, Sci. Rep. 9 (2019), pp. 17174. doi: 10.1038/s41598-019-53376-y.
   PubMed Web of Science ®Google Scholar
• C.A. Luckhurst, O. Aziz, V. Beaumont, R.W. Bürli, P. Breccia, M.C. Maillard, A.F. Haughan, M. Lamers, P. Leonard, K.L. Matthews, G. Raphy, A.J. Stott, I. Munoz-Sanjuan, B. Thomas, M. Wall, G. Wishart, D. Yates, and C. Dominguez, Development and characterization of a CNS-penetrant benzhydryl hydroxamic acid class IIa histone deacetylase inhibitor, Bioorg. Med. Chem. Lett. 29 (2019), pp. 83–88. doi: 10.1016/j.bmcl.2018.11.009.
   PubMed Web of Science ®Google Scholar
• P. Trivedi, N. Adhikari, S.A. Amin, Y. Bobde, R. Ganesh, T. Jha, and B. Ghosh, Design, synthesis, biological evaluation and molecular docking study of arylcarboxamido piperidine and piperazine-based hydroxamates as potential HDAC8 inhibitors with promising anticancer activity, Eur. J. Pharm. Sci. 138 (2019), pp. 105046. doi: 10.1016/j.ejps.2019.105046.
   PubMed Web of Science ®Google Scholar
• K. Vögerl, N. Ong, J. Senger, D. Herp, K. Schmidtkunz, M. Marek, M. Müller, K. Bartel, T.B. Shaik, N.J. Porter, D. Robaa, D.W. Christianson, C. Romier, W. Sippl, M. Jung, and F. Bracher, Synthesis and biological investigation of phenothiazine-based benzhydroxamic acids as selective histone deacetylase 6 inhibitors, J. Med. Chem. 62 (2019), pp. 1138–1166. doi: 10.1021/acs.jmedchem.8b01090.
   PubMed Web of Science ®Google Scholar
• K. Tilekar, N. Upadhyay, N. Jänsch, M. Schweipert, P. Mrowka, F.J. Meyer-Almes, and C. Ramaa, Discovery of 5-naphthylidene-2,4-thiazolidinedione derivatives as selective HDAC8 inhibitors and evaluation of their cytotoxic effects in leukemic cell lines, Bioorg. Chem. 95 (2019), pp. 103522. doi: 10.1016/j.bioorg.2019.103522.
   PubMed Web of Science ®Google Scholar